Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.

Hepatorenal syndrome is a severe complication of advanced liver cirrhosis, in patients with ascites and marked circulatory dysfunction. It is clearly established that it has a functional nature, and that it is related to intense renal vasoconstriction. Despite its functional origin, the prognosis is very poor. In the present review, the most recent advances in diagnosis, pathophysiology, and treatment are discussed. Recent developments in pathophysiology are the basis of the new therapeutic strategies, which are currently under evaluation in randomised clinical trials.

• Publication year

  2008

• Venue

  Journal of Hepatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2008.01.010PMID 18304678
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

  2008cited by this paper
• Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis

  2008cited by this paper
• Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.

  2007cited by this paper
• Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome

  2007cited by this paper
• Carbon Monoxide-Mediated Activation of Large-Conductance Calcium-Activated Potassium Channels Contributes to Mesenteric Vasodilatation in Cirrhotic Rats

  2007cited by this paper
• Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome

  2007cited by this paper
• Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.

  2007cited by this paper
• [82] RANDOMIZED, COMPARATIVE STUDY OF TERLIPRESSIN AND ALBUMIN VS ALBUMIN ALONE IN PATIENTS WITH CIRRHOSIS AND HEPATORENAL SYNDROME

  2007cited by this paper
• The Systemic Circulation in Cirrhosis

  2007cited by this paper
• Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

  2007cited by this paper
• Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.

  2007cited by this paper
• Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features

  2007cited by this paper
• TIPS versus paracentesis for cirrhotic patients with refractory ascites.

  2006cited by this paper
• Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival

  2006cited by this paper
• Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost

  2006cited by this paper
• Hepatology highlights

  2006cited by this paper
• Ascites and Renal Dysfunction in Liver Disease

  2005cited by this paper
• Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis.

  2005cited by this paper
• LIVER FAILURE AND LIVER DISEASE

  2005cited by this paper
• Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score.

  2005cited by this paper
• Hepatorenal syndrome

  2005cited by this paper
• The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites

  2005cited by this paper
• Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome

  2004cited by this paper
• Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis.

  2004cited by this paper
• New pathophysiological mechanisms in irritable bowel syndrome

  2004cited by this paper
• Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis

  2004cited by this paper
• Prognosis of hepatorenal syndrome – has it changed with current practice?

  2004cited by this paper
• Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

  2004cited by this paper
• LIVER FAILURE AND LIVER DISEASE

  2004cited by this paper
• Hepatorenal syndrome.

  2003cited by this paper
• Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.

  2003cited by this paper
• Acute renal failure in patients with cirrhosis: Perspectives in the age of MELD

  2003cited by this paper
• The North American Study for the Treatment of Refractory Ascites.

  2003cited by this paper
• Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis

  2003cited by this paper
• Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial

  2003cited by this paper
• Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat.

  2002cited by this paper
• Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study*

  2002cited by this paper
• Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study

  2002cited by this paper
• Albumin as a drug: biological effects of albumin unrelated to oncotic pressure

  2002cited by this paper
• Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

  2002influential reference
• Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis

  2002cited by this paper
• Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study

  2002cited by this paper
• Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2

  2002cited by this paper
• The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough

  2002cited by this paper
• Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.

  2001cited by this paper
• Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.

  2001cited by this paper
• Postprandial middle cerebral arterial vasoconstriction in cirrhotic patients. A placebo, controlled evaluation.

  2001cited by this paper
• Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.

  2000cited by this paper
• A COMPARISON OF PARACENTESIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTING IN PATIENTS WITH ASCITES

  2000cited by this paper
• Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

  2000cited by this paper
• Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial

  2000cited by this paper
• Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?

  2000cited by this paper
• A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.

  2000cited by this paper
• Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

  1999cited by this paper
• Long‐term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

  1999cited by this paper
• Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

  1999cited by this paper
• Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems.

  1998cited by this paper
• Reduction of renal cortical blood flow assessed by doppler in cirrhotic patients with refractory ascites

  1998cited by this paper
• Increased cerebrovascular resistance in cirrhotic patients with ascites

  1998cited by this paper
• Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems.

  1998cited by this paper
• Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

  1998cited by this paper
• Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome.

  1998cited by this paper
• Acute effects of the oral administration of midodrine, an α‐adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites

  1998cited by this paper
• Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems

  1998cited by this paper
• Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity

  1997cited by this paper
• Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE.

  1997cited by this paper
• Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.

  1996cited by this paper
• Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists.

  1996cited by this paper
• Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis

  1996cited by this paper
• Amelioration of hepatorenal syndrome with selective endothelin-A antagonist.

  1996cited by this paper
• Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis.

  1996cited by this paper
• Cirrhosis and muscle cramps: Evidence of a causal relationship

  1996cited by this paper
• Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial

  1996cited by this paper
• Cirrhotic cardiomyopathy: Getting to the heart of the matter

  1996cited by this paper
• Middle cerebral artery blood flow velocity in patients with cirrhosis

  1995cited by this paper
• IMPACT OF PRETRANSPLANT RENAL FUNCTION ON SURVIVAL AFTER LIVER TRANSPLANTATION

  1995influential reference
• Impact of pretransplant renal function on survival after liver transplantation.

  1995cited by this paper
• Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis

  1995cited by this paper
• Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis

  1995cited by this paper
• Hepatorenal Disorders: Role of the Sympathetic Nervous System

  1994cited by this paper
• Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis

  1994influential reference
• Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites

  1994cited by this paper
• Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis

  1993influential reference
• Renal vasoconstriction in cirrhosis evaluated by duplex doppler ultrasonography

  1993cited by this paper
• Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.

  1993cited by this paper
• Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction

  1993cited by this paper
• Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver.

  1993cited by this paper
• Capillary Blood Flow to the Skin of Forearm in Cirrhosis

  1992cited by this paper
• Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats.

  1992cited by this paper
• Increased production of cysteinyl leukotrienes in hepatorenal syndrome.

  1990cited by this paper
• Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure.

  1989cited by this paper
• Ascites and renal dysfunction in liver disease

  1989cited by this paper
• Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis

  1988cited by this paper
• Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome.

  1987cited by this paper
• Urinary excretion of 6-keto-prostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome).

  1986cited by this paper
• Urinary excretion of 6-keto-prostaglandin F1α, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites

  1986cited by this paper
• Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac.

  1986cited by this paper
• The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.

  1985cited by this paper
• Sympathetic nervous activity, renin‐angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion

  1983cited by this paper
• Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors.

  1983cited by this paper

• Hepato-Renal Crosstalk in Acute and Chronic Disease: From Shared Pathways to Therapeutic Targets

  2025cites this paper
• Efficacy and Safety of Terlipressin Infusion in Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI): A Retrospective Observational Study

  2024cites this paper
• The Renin–Angiotensin System in Liver Disease

  2024cites this paper
• Sindromul hepatorenal la copii

  2024cites this paper
• Clinical characteristics of hepatopulmonary syndrome and hepatorenal syndrome and associated therapeutic potential of transjugular intrahepatic portosystemic shunt

  2023cites this paper
• The Prevalence and Outcomes of Hepatorenal Syndrome in Chronic Liver Disease Patients in a Tertiary Care Hospital

  2023cites this paper
• Resuscitation and Preparation of the Emergency General Surgery Patient.

  2023cites this paper
• study of the effect of terlipressin with albumin vs only albumin in patients diagnosed with hepatorenal syndrome (HRS)

  2022cites this paper
• Advances in the Management of Renal Dysfunction in Patients With Cirrhosis.

  2021cites this paper
• Disfunción renal en el paciente cirrótico

  2021cites this paper
• Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis.

  2021cites this paper
• The Influence of Transcranial Magnetoacoustic Stimulation Parameters on the Basal Ganglia-Thalamus Neural Network in Parkinson’s Disease

  2021cites this paper
• Living Donor Liver Transplant in patients with Hepatorenal Syndrome without the use of Intraoperative Renal Replacement Therapy, a single‐center experience

  2021cites this paper
• Clinical Practice of Hepatorenal Syndrome: A Brief Review on Diagnosis and Management

  2021cites this paper
• Splanchnic and systemic circulation cross talks: Implications for hemodynamic management of liver transplant recipients.

  2020cites this paper
• IMMUNE MECHANISMS FOR THE DEVELOPMENT OF HEPATORENAL SYNDROME IN LIVER CIRRHOSIS

  2020cites this paper
• Urinary neutrophil gelatinase‐associated lipocalin determines short‐term mortality and type of acute kidney injury in cirrhosis

  2020cites this paper
• Hepatorenal syndrome in children: a review

  2020cites this paper
• Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome

  2020cites this paper
• Diagnosis in the Emergency Department – a continuous challenge (case report)

  2020cites this paper
• Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence

  2019cites this paper
• Pharmacological treatment of hepatorenal syndrome: a network meta-analysis

  2019cites this paper
• News in Pathophysiology, Definition and Classification of Hepatorenal Syndrome: a step beyond the International Club of Ascites (ICA) Consensus document.

  2019cites this paper
• Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2

  2019cites this paper
• Pathophysiology and Management of the Hepatorenal Syndrome

  2019cites this paper
• Cholemic Nephropathy: Hyperbilirubinemia and its Impact on Renal Function

  2019influential citation
• Functional magnetic resonance imaging-based assessment of terlipressin vs. octreotide on renal function in cirrhotic patients with acute variceal bleeding (CHESS1903): study protocol of a multicenter randomized controlled trial.

  2019cites this paper
• A Novel Biomarker for the Acute Kidney Injury in the Cirrhotic Patients

  2019cites this paper
• Factors associated with non-response to lactulose therapy in cirrhotic patients with minimal hepatic encephalopathy

  2018cites this paper
• HEPATORENAL SYNDROME: A REVIEW

  2018cites this paper
• Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1

  2018cites this paper
• Oxidative stress, NOx/l-arginine ratio and glutathione/glutathione S-transferase ratio as predictors of ‘sterile inflammation’ in patients with alcoholic cirrhosis and hepatorenal syndrome type II

  2018cites this paper
• Hepatorenal syndrome: the clinical impact of vasoactive therapy

  2018cites this paper
• Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications

  2018cites this paper
• Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study

  2018cites this paper
• Valoración de la Función Ventricular Izquierda en la Cirrosis Hepática: Relación con la Hemodinámica Sistémica y la Disfunción Renal

  2018cites this paper
• JMSCR Vol||05||Issue||02||Pages 17926-17939||February

  2017cites this paper
• The Role of Renal Resistive Index in Assessing the Early Renal Dysfunction of Cirrhosis

  2017cites this paper
• Challenges in Renal Failure Treatment Before Liver Transplant.

  2017cites this paper
• Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1.

  2017cites this paper
• Urinary Neutrophil Gelatinase Associated Lipocalin as a Biomarker for Diagnosis and Prognosis of Acute Kidney Injury (AKI) in Cirrhotic Patients

  2017cites this paper
• Impact of Acute Kidney Injury on Mortality of Patients Hospitalized for Complications of Cirrhosis.

  2017cites this paper
• La noradrenalina como tratamiento médico alternativo a la terlipresina en el manejo del síndrome hepatorrenal tipo 1

  2017cites this paper
• Renin angiotensin system in liver diseases: Friend or foe?

  2017cites this paper
• Predictors of response to terlipressin plus albumin therapy in hepatorenal syndrome (HRS) type 1

  2017cites this paper
• A Study of Renal Indices in Liver Cirrhosis

  2017cites this paper
• Hepatorenal syndrome.

  2016cites this paper
• Modulation of splanchnic circulation: Role in perioperative management of liver transplant patients.

  2016cites this paper
• Guías clínicas de diagnóstico y tratamiento de la ascitis Aspectos terapéuticos de la ascitis complicada y síndrome hepatorrenal Guías de diagnóstico y tratamiento en gastroenterología

  2016cites this paper
• Hepatorenal Syndrome: Diagnosis and Treatment – newsreel –

  2016cites this paper
• Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis

  2016cites this paper
• Assessment of aquo-ethanolic extract of Camellia sinensis against Carbapenem Resistant Escherichia coli: In Vivo Trials in a Murine Model.

  2016cites this paper
• Acute kidney injury in acute on chronic liver failure

  2016cites this paper
• Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study

  2016cites this paper
• Renal insufficiency in the patient with chronic liver disease.

  2015cites this paper
• Pathogenesis, Diagnosis and Treatment of Renal Dysfunction in Cirrhosis

  2015cites this paper
• Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes

  2015cites this paper
• Sepsis-induced acute kidney injury in patients with cirrhosis

  2015cites this paper
• Urine neutrophil gelatinase-associated lipocalin: a diagnostic and prognostic marker for acute kidney injury (AKI) in hospitalized cirrhotic patients with AKI-prone conditions

  2015cites this paper
• Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome.

  2015cites this paper
• Diabetes increases renovascular impedance in patients with liver cirrhosis

  2015cites this paper
• Patogenia, diagnóstico y tratamiento de la disfunción renal en cirrosis Pathogenesis, Diagnosis and Treatment of Renal Dysfunction in Cirrhosis

  2015cites this paper
• Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial

  2015cites this paper
• Insuficiencia renal en la cirrosis: Evaluación de nuevas clasificaciones pronósticas y tratamiento del síndrome hepato-renal tipo 1 asociado a sepsis

  2015cites this paper
• Transient increase in urine protein excretion during treatment with terlipressin and albumin for type-1 hepatorenal syndrome

  2015cites this paper
• DIAGNOSTIC AND TREATMENT OPTIONS OF HEPATORENAL SYNDROME IN CIRRHOSIS

  2015cites this paper
• Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.

  2014influential citation
• Impact of Hepatic Cirrhosis on Outcome in Adult Cardiac Surgery

  2014cites this paper
• Glomerular filtration rate equations for liver‐kidney transplantation in patients with cirrhosis: Validation of current recommendations

  2014cites this paper
• Cardiac Output Changes in Hepatorenal Syndrome

  2014cites this paper
• Transient increase in urine protein excretion during treatment with terlipressin and albumin for type-1 hepatorenal syndrome.

  2014cites this paper
• STUDY OF RESISTIVE INDEX IN VARIOUS STAGES OF LIVER CIRRHOSIS AND ITS SIGNIFICANCE IN CALCULATING THE RISK FOR HEPATORENAL SYNDROME

  2014cites this paper
• Liver Cirrhosis, Hepatorenal Syndrome, Renal Doppler.

  2014cites this paper
• The Effect of Octreotide on Urine Output During Orthotopic Liver Transplantation and Early Postoperative Renal Function; A Randomized, Double-Blind, Placebo-Controlled Trial

  2013cites this paper
• A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis.

  2013cites this paper
• LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction.

  2013cites this paper
• Post-Bypass Extensive Ascites due to Splanchnic Bypass and the Effectiveness of Hyperalimentation Treatment

  2013cites this paper
• Prediction of Hepatorenal Syndrome by Model of End Stage Liver Disease Score

  2013cites this paper
• Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice.

  2012cites this paper
• Revision and update on clinical practice guideline for liver cirrhosis

  2012cites this paper
• Management of Liver Cirrhosis

  2012cites this paper
• Disorders of Sodium Balance

  2012cites this paper
• The use of vasoconstrictors in patients with liver cirrhosis: how, when, why

  2012influential citation
• Arterial pressure profile in patients with cirrhosis: Fourier analysis of arterial pulse in relation to pressure level, stroke volume, and severity of disease: On the reduction of afterload in the hyperdynamic syndrome

  2012cites this paper
• Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis.

  2012cites this paper
• Treatment of ascites and spontaneous bacterial peritonitis - part I.

  2012cites this paper
• Invasive aspergillosis in patients with liver disease.

  2011cites this paper
• Terlipressin: An Asset for Hepatologists!

  2011cites this paper
• Role of Infections in Hepatorenal Syndrome

  2011cites this paper
• Serum cystatin C in advanced liver cirrhosis and different stages of the hepatorenal syndrome.

  2011cites this paper
• Medical Progress Renal Failure in Cirrhosis

  2011cites this paper
• DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY Terlipressin : An Asset for Hepatologists !

  2011cites this paper
• Organo Ufficiale della Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti - FADOI

  2011cites this paper
• Regulation of the Extracellular Fluid Volume and Renal Function

  2011cites this paper
• Management of Refractory Ascites and Hepatorenal Syndrome

  2011cites this paper
• Noninvasive predictors for the presence of gastroesophageal varices in patients with liver cirrhosis

  2011cites this paper
• End-stage liver disease: challenges and practice implications.

  2010cites this paper
• Prise en charge et surveillance de la cirrhose

  2010cites this paper
• Zaawansowana marskość wątroby - prowadzenie pacjentów oczekujących na przeszczepienie wątroby

  2010cites this paper
• The evaluation of renal function and disease in patients with cirrhosis.

  2010cites this paper